Physician profile
Sunitha Alluri
NPI 1750673125
$1,525.40
in general payments reported to CMS, 2019-2025
24 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $177 · 2023: $250 · 2024: $415 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intera Oncology, INC | $236.98 | 2024-2025 | Intera |
| Astrazeneca Pharmaceuticals LP | $157.74 | 2023-2025 | Imjudo, Imfinzi, Lynparza |
| Novocure INC. | $131.08 | 2023 | Optune |
| Medtronic, INC. | $130.02 | 2024 | Signia |
| Davol INC. | $104.12 | 2024 | Arista Ah Flexitip |
| Angiodynamics, INC. | $79.59 | 2025 | Nanoknife |
| Jazz Pharmaceuticals INC. | $72.84 | 2024-2025 | |
| Gilead Sciences, INC. | $69.65 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $67.08 | 2022-2025 | Rybrevant, Erleada |
| Integra Lifesciences Corporation | $66.20 | 2022 | |
| Sobi, INC | $62.97 | 2023-2025 | |
| Mirati Therapeutics, INC. | $41.33 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $40.88 | 2022-2023 | |
| Pfizer INC. | $39.02 | 2023-2024 | |
| Pharmaessentia USA Corporation | $31.59 | 2025 | Besremi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.10 | 2022 | |
| Daiichi Sankyo INC. | $28.99 | 2024 | Enhertu, Vanflyta |
| Abbvie INC. | $25.07 | 2025 | |
| Dendreon Pharmaceuticals LLC | $24.69 | 2025 | Provenge |
| Glaxosmithkline, LLC. | $22.01 | 2022 | |
| Foundation Medicine, INC. | $17.60 | 2023 | |
| Incyte Corporation | $16.26 | 2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $15.40 | 2025 | Iclusig |
| Myriad Genetic Laboratories, INC. | $13.19 | 2023 | Precisetumor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Alluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.